Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial
dc.contributor.author | Demers, Anne-Marie | en_ZA |
dc.contributor.author | Kim, Soyeon | en_ZA |
dc.contributor.author | McCallum, Sara | en_ZA |
dc.contributor.author | Eisenach, Kathleen | en_ZA |
dc.contributor.author | Hughes, Michael | en_ZA |
dc.contributor.author | Naini, Linda | en_ZA |
dc.contributor.author | Mendoza-Ticona, Alberto | en_ZA |
dc.contributor.author | Pradhan, Neeta | en_ZA |
dc.contributor.author | Narunsky, Kim | en_ZA |
dc.contributor.author | Poongulali, Selvamuthu | en_ZA |
dc.contributor.author | Badal-Faesen, Sharlaa | en_ZA |
dc.contributor.author | Upton, Caryn | en_ZA |
dc.contributor.author | Smith, Elizabeth | en_ZA |
dc.contributor.author | Shah, N. S. | en_ZA |
dc.contributor.author | Churchyard, Gavin | en_ZA |
dc.contributor.author | Gupta, Amita | en_ZA |
dc.contributor.author | Hesseling, Anneke | en_ZA |
dc.contributor.author | Swindells, Susan | en_ZA |
dc.date.issued | 2021-02-24 | |
dc.description | Demers, A. M., et al. 2021. Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial. BMC Infectious Diseases, 21:205, doi:10.1186/s12879-021-05884-4 | |
dc.description.abstract | Background: Drug susceptibility testing (DST) patterns of Mycobacterium tuberculosis (MTB) from patients with rifampicin-resistant tuberculosis (RR-TB) or multidrug-resistant TB (MDR-TB; or resistant to rifampicin and isoniazid (INH)), are important to guide preventive therapy for their household contacts (HHCs). Methods: As part of a feasibility study done in preparation for an MDR-TB preventive therapy trial in HHCs, smear, Xpert MTB/RIF, Hain MTBDRplus, culture and DST results of index MDR-TB patients were obtained from routine TB programs. A sputum sample was collected at study entry and evaluated by the same tests. Not all tests were performed on all specimens due to variations in test availability. Results: Three hundred eight adults with reported RR/MDR-TB were enrolled from 16 participating sites in 8 countries. Their median age was 36 years, and 36% were HIV-infected. Routine testing on all 308 were confirmed as having RR-TB, but only 75% were documented as having MDR-TB. The majority of those not classified as having MDR-TB were because only rifampicin resistance was tested. At study entry (median 59 days after MDR-TB treatment initiation), 280 participants (91%) were able to produce sputum for the study, of whom 147 (53%) still had detectable MTB. All but 2 of these 147 had rifampicin DST done, with resistance detected in 89%. Almost half (47%) of the 147 specimens had INH DST done, with 83% resistance. Therefore, 20% of the 280 study specimens had MDR-TB confirmed. Overall, DST for second-line drugs were available in only 35% of the 308 routine specimens and 15% of 280 study specimens. Conclusions: RR-TB was detected in all routine specimens but only 75% had documented MDR-TB, illustrating the need for expanded DST beyond Xpert MTB/RIF to target preventive therapy for HHC. | |
dc.description.uri | https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-05884-4 | |
dc.description.version | Publisher's version | |
dc.format.extent | 10 pages | en_ZA |
dc.identifier.uri | http://hdl.handle.net/10019.1/110410 | |
dc.language.iso | en_ZA | en_ZA |
dc.publisher | BMC (part of Springer Nature) | en_ZA |
dc.rights.holder | Authors retain copyright | en_ZA |
dc.subject | Tuberculosis | en_ZA |
dc.subject | Drug resistance | en_ZA |
dc.subject | Antimicrobial susceptibility testing | en_ZA |
dc.subject | Mycobacterium tuberculosis | en_ZA |
dc.title | Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial | en_ZA |
dc.type | Article | en_ZA |